Bicycle Therapeutics plc
BCYC
$4.72
$0.020.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 47.96M | 11.73M | 2.92M | 9.98M | 3.71M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.96M | 11.73M | 2.92M | 9.98M | 3.71M |
| Cost of Revenue | 45.92M | 56.61M | 71.03M | 57.27M | 47.97M |
| Gross Profit | 2.04M | -44.88M | -68.11M | -47.29M | -44.26M |
| SG&A Expenses | 22.55M | 20.67M | 18.49M | 22.91M | 22.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.46M | 77.29M | 89.52M | 80.18M | 70.27M |
| Operating Income | -20.51M | -65.55M | -86.60M | -70.20M | -66.56M |
| Income Before Tax | -18.89M | -58.90M | -79.18M | -61.84M | -52.94M |
| Income Tax Expenses | 1.27M | 205.00K | -231.00K | -1.09M | -1.08M |
| Earnings from Continuing Operations | -20.15M | -59.10M | -78.95M | -60.75M | -51.85M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.15M | -59.10M | -78.95M | -60.75M | -51.85M |
| EBIT | -20.51M | -65.55M | -86.60M | -70.20M | -66.56M |
| EBITDA | -19.17M | -63.80M | -84.91M | -68.57M | -64.86M |
| EPS Basic | -0.29 | -0.85 | -1.14 | -0.88 | -0.75 |
| Normalized Basic EPS | -0.13 | -0.53 | -0.71 | -0.56 | -0.51 |
| EPS Diluted | -0.29 | -0.85 | -1.14 | -0.88 | -0.75 |
| Normalized Diluted EPS | -0.13 | -0.53 | -0.71 | -0.56 | -0.51 |
| Average Basic Shares Outstanding | 69.36M | 69.30M | 69.25M | 69.20M | 69.05M |
| Average Diluted Shares Outstanding | 69.36M | 69.30M | 69.25M | 69.20M | 69.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |